23rd International Symposium on Infections in the Critically Ill Patient

Abstract

IntroductionThis 23rd International Symposium on Infections in the Critically Ill Patient aims to review current concepts, technology and present advances in infections in critically ill patient.Sepsis, Pulmonary Infections and their therapeutic and preventive strategies will be the topics presented by international experts who will review and update sepsis as a global international problem. New guidelines of Surviving Sepsis campaign, fluid therapy and vassopressors, a balance view between personalization and protocol treatment and new recommendations for the design of future randomized control trials are provided. The immune response and the emerging methods to personalize sepsis care including new biomarkers and immunomonitoring of patients with sepsis represent a new complementary view to treat patients with severe infections and organ failure in addition to early antibiotic and the control of source of infection.New ways to treat pulmonary infections including the new global guidelines and the international actions against multiresistant microorganisms and the development of new antibiotics represent key factors to improve the outcome of severe infections. antibiotics, fluid resuscitation, blood pressure targets and so forth fails to account for the individualized needs of the patient. Sepsis is not a specific disease entity but an umbrella syndrome covering a range of biological phenotypes. Therapies should thus be selected and dose-adjusted accordingly, taking into account the individual host's phenotype, underlying comorbidities, and the site and source of infection. A one-size-fits-all, brain-stem, heavily protocolized approach will suit the lowest common denominator. Surely we should seek loftier ambitions based on education, an increased depth of understanding, enhanced monitoring and diagnostics, and a personalized approach incorporating evidence and clinical expertise. This concept of EBID (evidence-based individualized decision-making) is not new; indeed, it was enshrined by none other than David Sackett, a pioneer of evidence-based medicine who railed against rigid adoption of evidence: "Clinicians who fear top down cookbooks will find the advocates of evidence -based medicine joining them at the barricades". Ignacio Do We Need New Clinical Design for RCT? Jean-Louis VincentDepartment of Intensive Care, Erasme Hospital, Université libre de Bruxelles, Brussels, BelgiumAbstract: The prospective randomized controlled trial (RCT) has been widely promoted as the only effective means of definitively proving the superiority of one intervention over another. However, in the intensive care unit (ICU) population, RCTs can be challenging to conduct, and results have rarely demonstrated beneficial effects of the intervention under investigation on outcomes. The main reason for this lack of success is the heterogeneous nature of the critically ill populations included in these studies. Ethical issues can also be a problem in the ICU as patients are frequently not able to give consent and surrogates may not be ...

Changes of rScO2 and ScvO2 in childrenwith sepsis‑related encephalopathywith different prognoses and clinical features

“…Central venous oxygen saturation (ScvO 2 ) can be used for targeted screening of patients with early sepsis (5). In addition, a study has found that regional cerebral oxygen saturation (rScO 2 ) is closely related to ScvO 2 (6). The present study included 80 children with sepsis-related encephalopathy who were admitted to the Pediatric Intensive Care Unit (PICU) of the Children's Hospital Affiliated to Zhengzhou University (Zhengzhou, China) from January 2015 to January 2018.…”

Synthesis and Phase Transformation Studies of Dysprosium-Doped Bi4V2O11 Nanoparticles and Their Application in Visible Light Photocatalytic Degradation of Tetracycline Drug

“…6 It is accounted for that TC sedate is the beside the biggest utilized as a part of the world, representing right around 33% of the anti-infection agents creation and utilization. 7 , 8 With the unnecessary gathering of antibiotic agents in the human body, 9 they can incite nephropathy, influence kidneys, and different changes, for example, mutagenic and teratogenic impacts. 5 The presence of TC drug in water conditions will influence the structure and action of microorganisms, which subsequently changes the natural structure of the microbial vegetation.…”

“…Tetracycline (TC) drug is broadly utilized as a part of different perspectives, for example, bacterial infection, horticulture, and domesticated animal products . It is accounted for that TC sedate is the beside the biggest utilized as a part of the world, representing right around 33% of the anti-infection agents creation and utilization. , With the unnecessary gathering of antibiotic agents in the human body, they can incite nephropathy, influence kidneys, and different changes, for example, mutagenic and teratogenic impacts . The presence of TC drug in water conditions will influence the structure and action of microorganisms, which subsequently changes the natural structure of the microbial vegetation. , In order to eliminate the residual antibiotics in ecological water, the current innovation is primarily reliant on activated carbon adsorption, coagulation–flotation, ultrasound degradation, and membrane bioreactor .…”